1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Zydus Looks To NASH Trials In Turkey, Generic Vascepa Launch In The US

Generic Versions Of Revlimid And Trokendi Drive Record US Sales

 
• By Vibha Ravi

Zydus, the only Indian company with an NCE for a range of chronic liver diseases, will add Turkey to the list of trial locations for NASH. It is also working “aggressively” to launch a generic to Amarin’s Vascepa after Revlimid and Trokendi generics drove record US sales in the fourth quarter.

Earnings growth vector
Zydus Is Nurturing New Molecules For The Future Even As Generics Pay Off For Now • Source: Shutterstock

The US Food and Drug Administration’s negative review for Intercept Pharmaceuticals’s obeticholic acid has set off questions about the fate of other non-alcoholic steatohepatitis (NASH) drug hopefuls.

Among them is Zydus Lifesciences Limited, the sole Indian company evaluating a New Chemical Entity saroglitazar magnesium against chronic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Krka Passes €1bn Threshold In Just Six Months

 
• By Dean Rudge

Krka has reported its strongest-ever half-year results, surpassing €1bn in sales and growing EBITDA by 8%. Solid performance across most regions, particularly Eastern and Central Europe, supported stable margins and a positive full-year outlook.

Kirsty Gives Biocon A First Interchangeable US Insulin Aspart Biosimilar

 
• By Dave Wallace

After years of waiting, Biocon Biologics has finally snagged US FDA approval for its insulin aspart biosimilar – along with a first designation of interchangeability. However, Sanofi’s Merilog version is already approved as a rival to Novo Nordisk’s Novolog.

Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review

 
• By Dave Wallace

As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.